Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma

Sponsor
Masaryk Hospital Krajská zdravotní a.s. (Other)
Overall Status
Unknown status
CT.gov ID
NCT03634215
Collaborator
(none)
200
10.5

Study Details

Study Description

Brief Summary

Coagulation factor XIII (FXIII), a plasma transglutaminase, is known as the final enzyme of the coagulation cascade, responsible for a cross-linking of fibrin to strengthen blood clot. It also minimizes fibrin degradation by its cross-linking it with alfa2-antiplasmin molecules. It has been found that similar to plasma fibrinogen level, FXIII activity can be reduced in the early phase of severe trauma. Therefore, its immediate substitution is of potential therapeutic interest in trauma-induced coagulopathy. However, unlike plasma fibrinogen level evaluation, measurement of the FXIII activity is not routinely available. Therefore, targeted substitution of FXIII is practically impossible. The plasma fibrinogen level is routinely measured in severe trauma patients. Based on pathophysiologic assumptions and a limited number of published data we hypothesize that the FXIII activity correlates with fibrinogen level. In such case, indirect FXIII activity prediction by fibrinogen level measurement would be a convenient approach to enable FXIII targeted substitution. Therefore we decided to perform a prospective observational clinical trial to determine whether the low plasma fibrinogen level in severe trauma correlates with decreased FXIII activity.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: fibrinogen plasma concentration, coagulation factor XIII activity

Detailed Description

Coagulation factor XIII (FXIII), a plasma transglutaminase, is known as the final enzyme of the coagulation cascade, responsible for a cross-linking of fibrin to strengthen blood clot. It also minimizes fibrin degradation by its cross-linking it with alfa2-antiplasmin molecules. It has been found that similar to plasma fibrinogen level, FXIII activity can be reduced in the early phase of severe trauma. Therefore, its immediate substitution is of potential therapeutic interest in trauma-induced coagulopathy. However, unlike plasma fibrinogen level evaluation, measurement of the FXIII activity is not routinely available. Therefore, targeted substitution of FXIII is practically impossible. The plasma fibrinogen level is routinely measured in severe trauma patients. Based on pathophysiologic assumptions and a limited number of published data we hypothesize that the FXIII activity correlates with fibrinogen level. In such case, indirect FXIII activity prediction by fibrinogen level measurement would be a convenient approach to enable FXIII targeted substitution. Therefore we decided to perform a prospective observational clinical trial to determine whether the low plasma fibrinogen level in severe trauma correlates with decreased FXIII activity.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma
Anticipated Study Start Date :
Aug 15, 2018
Anticipated Primary Completion Date :
Dec 31, 2018
Anticipated Study Completion Date :
Jun 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Multiple Trauma patients

Diagnostic Test: fibrinogen plasma concentration, coagulation factor XIII activity
blood sampling for a routine coagulation test

Outcome Measures

Primary Outcome Measures

  1. coagulation factor XIII activity [1 day]

    coagulation factor XIII activity expressed as % of the normal value

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • a patient with presumed severe trauma admitted to the participating centre
Exclusion Criteria:
  • inflammatory disease

  • malignant disease

  • pregnancy

  • receipt of any fibrinogen / coagulation factor XIII product before blood sampling

  • patients on dabigatran

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Masaryk Hospital Krajská zdravotní a.s.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Josef Skola, Clinical Director, Masaryk Hospital Krajská zdravotní a.s.
ClinicalTrials.gov Identifier:
NCT03634215
Other Study ID Numbers:
  • KAPIM-2
First Posted:
Aug 16, 2018
Last Update Posted:
Aug 16, 2018
Last Verified:
Aug 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2018